Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KW-8232, an orally active anti-osteoporotic agent, reduces the biosynthesis of PGE2[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | KW-8232, an orally active anti-osteoporotic agent, reduces the biosynthesis of PGE2[1]. |
In vitro | KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM )[2]. |
In vivo | KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1]. |
Molecular Weight | 705.27 |
Formula | C37H41ClN4O6S |
CAS No. | 217813-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (177.24 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KW-8232 217813-15-5 KW 8232 KW8232 inhibitor inhibit